An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination With PD-1 Blockade in Patients With Solid Tumors

Study Summary

This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single agent and in combination with anti-PD1 therapy and to determine the recommended Phase 2 dose (RP2D) of RP3.

Interventions

Study Locations

Facility	City	State	Country
University of Iowa	Iowa City	Iowa	United States
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	United States
MD Anderson Cancer Center	Houston	Texas	United States
Laboratoire de Recherche Translationnelle en Immunotherapie (LRTI), Gustave Roussy	Villejuif		France
University of Athens	Athens		Greece
University General Hospital Attikon	Athens		Greece
Vall d'Hebron Hospital Hospital Universitario Vall d´Hebron (Vall d'Hebron University Hospital)	Barcelona		Spain
Hospital Clinic Barcelona	Barcelona		Spain
START Madrid CIO Clara Campal, Hospital Universitario HM Sanchinarro Unidad de Ensayos Fase I Panta 3	Madrid		Spain
Hospital Clinico Universitario de Valencia	Valencia		Spain
The Clatterbridge Cancer Centre NHS Foundation Trust	Bebington	Merseyside	United Kingdom
The Royal Marsden NHS Foundation Trust	London		United Kingdom
Churchill Hospital	Oxford		United Kingdom

Official Trial Information

View on ClinicalTrials.gov